← Back to Search

Radiation

99mTc-MAA Injection for Cancer (MAApping Trial)

Phase 4
Waitlist Available
Led By Douglas Murrey, MD
Research Sponsored by Sirtex Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18-24 hours
Awards & highlights

MAApping Trial Summary

This trial tests a new radiation dose for liver cancer treatment to reduce damage to other parts of the body.

Eligible Conditions
  • Cancer
  • Hepatocellular Carcinoma
  • Liver Cancer

MAApping Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18-24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18-24 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Effective dose (Gy) for the whole body
Mean absorbed dose (Gy) for critical non-liver organs
Mean absorbed dose (Gy) for the whole body
+2 more

MAApping Trial Design

1Treatment groups
Experimental Treatment
Group I: 99mTc-MAA InjectionExperimental Treatment1 Intervention
Patients enrolled in the study will have 3 imaging scans taken after 99mTc-MAA Injection with the final scan occurring 18-24 hours after injection.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
99mTc-Macro Albumin Aggregate
2023
Completed Phase 4
~10

Find a Location

Who is running the clinical trial?

Sirtex MedicalLead Sponsor
28 Previous Clinical Trials
4,265 Total Patients Enrolled
Bright Research PartnersIndustry Sponsor
13 Previous Clinical Trials
1,749 Total Patients Enrolled
Douglas Murrey, MDPrincipal InvestigatorInland Imaging

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Apr 2025